Bridgeway Capital Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Bridgeway Capital Management’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-52,400	Closed	-$576K	–	1482
2017 Q2	$576K	Hold	52,400	–	–	0.01%	1042
2017 Q1	$514K	Hold	52,400	–	–	0.01%	1067
2016 Q4	$566K	Buy	52,400 +10,300	+24%	+$103K	0.01%	1047
2016 Q3	$432K	Sell	42,100 -550	-1%	-$5.99K	0.01%	1147
2016 Q2	$557K	Sell	42,650 -12,500	-23%	-$164K	0.01%	998
2016 Q1	$607K	Sell	55,150 -171,800	-76%	-$1.53M	0.01%	966
2015 Q4	$2.09M	Buy	226,950 +16,700	+8%	+$140K	0.04%	487
2015 Q3	$1.46M	Buy	210,250 +43,600	+26%	+$373K	0.03%	587
2015 Q2	$1.64M	Hold	166,650	–	–	0.03%	588
2015 Q1	$1.48M	Hold	166,650	–	–	0.03%	638
2014 Q4	$1.46M	Hold	166,650	–	–	0.03%	637
2014 Q3	$1.15M	Hold	166,650	–	–	0.03%	705
2014 Q2	$877K	Buy	166,650 +4,900	+3%	+$23.8K	0.02%	823
2014 Q1	$736K	Buy	161,750 +50,000	+45%	+$241K	0.02%	897
2013 Q4	$563K	Hold	111,750	–	–	0.02%	990
2013 Q3	$567K	Buy	+111,750	New	+$622K	0.02%	967

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bridgeway Capital Management's SCLN Position: Q3 2017 in Review

Bridgeway Capital Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 52,400 shares — an estimated $576K sold.

Bridgeway Capital Management first reported a position in SCLN in Q3 2013 and held it in 16 quarters. The position peaked at $2.09M in Q4 2015. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

Bridgeway Capital Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
Bridgeway Capital Management sold 52,400 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $576K.
Bridgeway Capital Management first reported a position in Sciclone Pharmaceuticals Inc in Q3 2013 and held it in 16 quarters.
Bridgeway Capital Management's Sciclone Pharmaceuticals Inc position peaked at $2.09M in Q4 2015.
129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Bridgeway Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.